5‐(4‐Methoxybenzylidene)thiazolidine‐2,4‐dione‐derived VEGFR‐2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluations
作者:Khaled El‐Adl、Helmy Sakr、Mohamed Nasser、Mohamed Alswah、Fatma M. A. Shoman
DOI:10.1002/ardp.202000079
日期:2020.9
4‐dione derivatives, 5a–g and 7a–f, was designed, synthesized, and evaluated for their anticancer activity against HepG2, HCT116, and MCF‐7 cells. HepG2 and HCT116 were the most sensitive cell lines to the influence of the new derivatives. In particular, compounds 7f, 7e, 7d, and 7c were found to be the most potent derivatives of all the tested compounds against the HepG2, HCT116, and MCF‐7 cancer cell
设计、合成了一系列新型 5-(4-甲氧基亚苄基)噻唑烷-2,4-二酮衍生物,5a-g 和 7a-f,并评估了它们对 HepG2、HCT116 和 MCF-7 细胞的抗癌活性。HepG2 和 HCT116 是对新衍生物影响最敏感的细胞系。特别是,发现化合物 7f、7e、7d 和 7c 是所有测试化合物中对抗 HepG2、HCT116 和 MCF-7 癌细胞系最有效的衍生物。化合物 7f(分别为 IC50 = 6.19 ± 0.5、5.47 ± 0.3 和 7.26 ± 0.3 µM)对 M 和 CFp2 的活性分别高于索拉非尼(IC50 = 9.18 ± 0.6、8.37 ± 0.7 和 5.10 ± 0.4 µM) ‐7, 细胞,但对 HCT116 癌细胞的活性较低。此外,该化合物显示出比阿霉素更高的活性(IC50 = 7.94 ± 0.6、8.07 ± 0.8 和 6.75 ± 0。分别为